{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Established Pharmacologic Class [EPC]" in comments (approximate match)
Status:
First approved in 1951
Class:
POLYMER
Status:
US Previously Marketed
Source:
DEXTRAN 6 PCT by PHARMACHEM
(1961)
Source URL:
First marketed in 1921
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
LACRISERT
Source URL:
First approved in 1995
Source:
Bio-Groom Lido-Med Veterinary Strength by Bio-Derm Laboratories Inc.
Source URL:
Class:
POLYMER
Targets:
Hydroxypropyl cellulose (HPC) is an ether of cellulose where some of the hydroxyl groups of the cellulose have been hydroxypropylated. Hydroxypropyl cellulose is used as an excipient, and topical ophthalmic protectant and lubricant. Hydroxypropyl cellulose, manufactured by Aton Pharma, is a formulation of HPC used for artificial tears. It is used to treat medical conditions characterized by insufficient tear production such as keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure, and neuroparalytic keratitis. HPC is also used as a lubricant for artificial eyes. Hydroxypropyl cellulose acts to stabilize and thicken the precorneal tear film and prolong the tear film breakup time which is usually accelerated in patients with dry eye states. Hydroxypropyl cellulose usually reduces the signs and symptoms resulting from moderate to severe dry eye syndromes, such as conjunctival hyperemia, corneal and conjunctival staining with rose bengal, exudation, itching, burning, foreign body sensation, smarting, photophobia, dryness, and blurred and cloudy vision. Progression visual deterioration which occurs in some patients may be retarded, halted, or sometimes reversed.
Status:
Possibly Marketed Outside US
Source:
NCT04432675: Phase 4 Interventional Completed Cesarean Section
(2022)
Source URL:
First approved in 1991
Source:
BN890105
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Canada:MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP C
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Canada:MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP A
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Canada:MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP W-135
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Canada:MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP Y
Source URL:
Class:
POLYMER
Status:
Discontinued
Source:
Pentaspan by Bristol Myers Squibb [Canada]
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(2011)
First approved in 2011
Class:
STRUCTURALLY DIVERSE